Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose MK-1167 study of brain glutamate cycling using 13C-MRS in healthy adults
NL-OMON51348Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of MK-1167 in Alzheimer's disease (AD), sponsored by Merck & Co. Primary endpoint: Effect of single oral doses of MK-1167 on glutamate metabolism in the prefrontal cortex. Started Aug 2022; status: completed.
02
Drugs
MK-1167
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON51348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51348.